An Australian biotech company is already turning heads so far on Wednesday after it was announced results from its GBM-AGILE, which is a phase...
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma PR...
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER PR...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement PR Newswire SYDNEY, May...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.